Metronomic Temozolomide in Unfit NENs Patients Metronomic Temozolomide in Unfit Patients With Advanced Neuroendocrine Neoplasms (NENs): MeTe Study

NCT05554003 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

46

Enrollment

OTHER

Sponsor class

Conditions

Neuroendocrine Tumors
Frailty
Chemotherapy Effect

Interventions

DRUG: Temozolomide capsule

Sponsor

European Institute of Oncology